Recent status of HIV-1 gene expression inhibitors

被引:51
作者
Baba, Masanori [1 ]
机构
[1] Kagoshima Univ, Div Antiviral Chemotherapy, Ctr Chron Viral Dis, Grad Sch Med & Dent Sci, Kagoshima 8908544, Japan
关键词
HIV-1; chemotherapy; transcription; Tat; NF-kappa B; IMMUNODEFICIENCY-VIRUS TYPE-1; NF-KAPPA-B; DEPENDENT KINASE INHIBITOR; SOCIETY-USA PANEL; RNA-POLYMERASE-II; P-TEFB; TAR RNA; ANTIVIRAL ACTIVITY; REV PROTEIN; PHASE-II;
D O I
10.1016/j.antiviral.2006.01.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human immiunodeficiency virus type 1 (HIV-1) gene expression and transcription is a crucial step in the viral replication cycle, which is considered to be a potential target for inhibition of HIV-1. Among the factors involved in this step, the cellular protein nuclear factor (NF)-kappa B is the most powerful inducer of HIV-1 gene expression. On the other hand, the viral protein Tat plays a central role in sustaining a high level of HIV-1 replication. Several compounds have been reported to selectively inhibit the functions of Tat and NF-kappa B. Tat inhibitors target either the Tat/TAR RNA interaction or the Tat cofactor cyclin-dependent kinase 9/cyclin T I. Antioxidants, protein kinase C inhibitors, and I kappa B kinase inhibitors are known to suppress the activation of NF-kappa B. Although some of the compounds inhibit HIV-1 replication in cell cultures at low concentrations, they also have considerable toxicity to the host cells. Considering the increase of treatment failure cases in highly active antiretroviral therapy due to the emergence of multidrug resistance, HIV-1 gene expression inhibitors should be extensively studied as alternative approach to effective anti-HIV-1 chemotherapy. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:301 / 306
页数:6
相关论文
共 49 条
  • [1] Antiviral activity of CYC202 in HIV-1-infected cells
    Agbottah, E
    de la Fuente, C
    Nekhai, S
    Barnett, A
    Gianella-Borradori, A
    Pumfery, A
    Kashanchi, F
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (04) : 3029 - 3042
  • [2] Baba M, 1998, MOL PHARMACOL, V53, P1097
  • [3] Inhibitors of HIV-1 gene expression and transcription
    Baba, M
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (09) : 871 - 882
  • [4] Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection
    Cabrera, C
    Gutiérrez, A
    Blanco, J
    Barretina, J
    Litovchick, A
    Lapidot, A
    Evdokimov, AG
    Clotet, B
    Esté, JA
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (07) : 627 - 634
  • [5] Daelemans D, 2000, MOL PHARMACOL, V57, P116
  • [6] A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export
    Daelemans, D
    Afonina, E
    Nilsson, J
    Werner, G
    Kjems, J
    De Clercq, E
    Pavlakis, GN
    Vandamme, AM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (22) : 14440 - 14445
  • [7] A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor
    Doranz, BJ
    GrovitFerbas, K
    Sharron, MP
    Mao, SH
    Goetz, MB
    Daar, ES
    Doms, RW
    OBrien, WA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (08) : 1395 - 1400
  • [8] NF-κB and rel proteins:: Evolutionarily conserved mediators of immune responses
    Ghosh, S
    May, MJ
    Kopp, EB
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 : 225 - 260
  • [9] Missing pieces in the NF-κB puzzle
    Ghosh, S
    Karin, M
    [J]. CELL, 2002, 109 : S81 - S96
  • [10] An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication
    Hamy, F
    Felder, ER
    Heizmann, G
    Lazdins, J
    AboulEla, F
    Varani, G
    Karn, J
    Klimkait, T
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) : 3548 - 3553